Friday, September 11, 2009
Sanofi-Aventis, Regeneron End Phase III Trial Of Aflibercept - Wall Street Journal
Sanofi-Aventis, Regeneron End Phase III Trial Of Aflibercept
Wall Street Journal
Shares of Regeneron fell 3% to $21.23 in after-hours trading. Sanofi-Aventis' American depositary shares closed Friday at $35.05, up 0.4%, and were inactive ...
and more »
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment